Home
Categories
Ingredients
Analysis
Manufacturing
Finance
Regulatory
Drug Delivery
Research & Development
Sustainability
Company News
Events
Directory
Search
Close search
Home
Company
MEI Pharma
MEI Pharma
Activities:
Research & Development
X
LinkedIn
Trending Articles
Catalent and AstraZeneca to expand support for COVID-19 vaccine AZD1222
Catalent will prepare the Harmans facility, close to Baltimore-Washington International (BWI) airport, to enable multiple production trains to run in parallel to produce the...
Overcoming CMC challenges in cell and gene therapy: part II
Certara’s Dr Hien Anh Bruno, Associate Director, Chemistry, Manufacturing and Controls (CMC), and Dr Deven Shah, CMC Lead, propose mitigation strategies to address the CMC...
SNIPR Biome receives funding to progress CRISPR medicine SNIPR001 into clinical trials
Phase 1b/2a trial will evaluate SNIPR001 for the prevention of E.coli infections in patients undergoing hematopoietic stem cell transplantation
Kindeva Drug Delivery appoints Denis Johnson as Chief Operating Officer
Denis will be responsible for optimising global operations for the company
SeaBeLife awarded over €1.5 million in i-Nov innovation competition
Funding for company’s SeaBeEYE project will be used to develop a new therapeutic approach for geographic atrophy, a form of age-related macular degeneration
Upcoming event
Cleanroom Conference UK
22–23 May 2024 | Exhibition | Birmingham, UK
See all
Related Content
Ingredients
Therapeutic: anticancer agent zandelisib
Phosphatidylinositol 3-kinase delta (PI3K[delta]) is commonly overexpressed in cancer cells. In particular, it plays a vital role in the proliferation and survival of haematologic cancers
Regulatory
Orphan drug designation for AML treatment
Helsinn Group and MEI Pharma announced that Pracinostat has received orphan drug designation from the European Medicines Agency (EMA) for the treatment of acute myeloid leukemia (AML)
Research & Development
Helsinn Group and MEI Pharma to develop acute myeloid leukaemia treatment
MEI Pharma to receive $20m, plus up to $444m in potential milestone payments as well as sales royalties
Subscribe now